Tumour markers Sample: blood Result: 1 working day

CEA (carcinoembryonic antigen)

CEA (carcinoembryonic antigen) is a tumour marker used especially in bowel (colorectal) cancer, but also in other cancers such as pancreatic, stomach, lung, breast and ovarian cancer and medullary thyroid carcinoma. It is useful for monitoring the course of the disease, detecting recurrence and assessing the response to treatment.

Test code C2546 Preparing for laboratory tests

Some laboratory tests require specific preparation by the patient, concerning diet before sampling and the time of day at which to come to the laboratory for sampling. The patient can be informed about this by their doctor or by the staff of Sante Laboratorije. Many other tests, however, need no prior preparation, and samples do not have to be collected at a particular time or in relation to meals.

For information, contact us on +381 11 27 62 199 | +381 64 65 87 607 or in writing at office@clinica-sante.rs.

Preparation and sampling

Preparation
Guide to preparing for tests
Sample
Blood
Results available in
1 working day
Where it is done
All laboratories and map

Description

About the test

Carcinoembryonic antigen (CEA) is a glycoprotein produced in large amounts during development in the womb, especially in the digestive system. After birth its production falls sharply, and adults normally have only small amounts in their blood.

Some tumour cells can produce CEA and release it into the blood. CEA is therefore used as a tumour marker, mainly to monitor bowel (colorectal) cancer. Measuring it can help assess the response to treatment and detect a possible return of the disease after treatment.

CEA can also be raised in other cancers, such as pancreatic, stomach, lung, breast and ovarian cancer or medullary thyroid carcinoma.

CEA levels can also rise in non-cancerous conditions such as liver disease, blockage of the bile ducts, pancreatitis, inflammatory bowel disease or some lung diseases. Smokers may also have higher values than non-smokers.

CEA cannot confirm or rule out a tumour on its own. When the disease is being monitored, the change in values over time is usually more important than a single result.

When it is recommended

  • establishing a baseline value before starting treatment for bowel cancer;
  • completing the assessment of prognosis in people diagnosed with bowel cancer;
  • monitoring the response to surgery, chemotherapy, radiotherapy or other cancer treatment;
  • follow-up of people treated for bowel cancer, to detect possible recurrence or progression;
  • monitoring other CEA-producing cancers in selected situations, especially when the marker was raised before treatment;
  • monitoring medullary thyroid carcinoma, together with calcitonin and the other investigations recommended by the doctor.

CEA is not recommended as a screening test for bowel cancer or other cancers. Bowel cancer screening uses specific tests, such as tests for hidden (occult) blood in the stool and colonoscopy.

Preparation

  • Fasting is usually not needed for the CEA test itself. If you are having other blood tests on the same day, follow the general rule: blood is taken in the morning, between 7 and 10 a.m., after 12 hours of fasting, and you may drink water as usual.
  • Tell your doctor if you smoke, as smoking can raise CEA.
  • Tell your doctor about your cancer diagnosis and when you had surgery, chemotherapy, radiotherapy or other treatment.
  • To establish a baseline value, the test is preferably done before treatment starts.
  • For monitoring, tests are done at the intervals recommended by your doctor.
  • Tell your doctor and the laboratory about any medicines and supplements you take. High doses of biotin (vitamin B7, common in hair and nail supplements) can change the result of some laboratory methods; with high doses a break is needed, usually 2–3 days, in agreement with your doctor.
  • Do not stop prescribed treatment without agreeing it with your doctor.
  • For monitoring over time, successive tests should ideally be done by the same method and, if possible, in the same laboratory.

Sample

Venous blood.

Reference values

Reference values for CEA depend on the method and reagents used by the laboratory. For orientation, the following values may be seen:

  • non-smokers: up to 3.0 ng/mL;
  • smokers: values may be higher, usually up to about 5.0 ng/mL.

CEA may be reported in ng/mL or µg/L; the two units have the same numerical value. Some laboratories use a single limit regardless of smoking status.

There is no universal CEA value that alone confirms cancer, its location or the presence of metastases.

Reference values depend on the method and the laboratory; the values printed on your report apply to your result.

Interpreting the results

A raised CEA does not by itself mean cancer. Interpretation depends on the person's medical history, smoking status, other conditions and how the result changes over time.

CEA can be raised in:

  • bowel (colorectal) cancer;
  • pancreatic or stomach cancer;
  • lung cancer;
  • breast cancer;
  • ovarian cancer;
  • medullary thyroid carcinoma;
  • other CEA-producing tumours.

Raised values can also occur in non-cancerous conditions, such as:

  • liver disease, including hepatitis, fatty liver and cirrhosis;
  • blockage of the bile ducts;
  • pancreatitis;
  • inflammatory bowel disease;
  • diverticulitis;
  • gastritis and stomach or duodenal ulcers;
  • some chronic lung diseases;
  • smoking.

In a person with known cancer, a fall in CEA after treatment may indicate a reduction in tumour tissue. Persistently raised values may raise the suspicion of residual disease, but further investigations are needed.

A gradual rise in CEA on successive measurements may suggest recurrence or progression. Such a change must be confirmed and compared with clinical examination and imaging.

Very high values, especially if they persist or keep rising, may be associated with more extensive disease. However, no threshold alone proves the presence of metastases.

A CEA within the reference range does not rule out cancer. Some tumours do not produce CEA, or produce too little of it to raise the blood level. If CEA was normal before treatment, it may be of limited use for later monitoring, and the disease is followed by clinical examination, imaging and other tests recommended by the doctor.

A low or undetectable CEA is considered normal and has no pathological significance. In a person under cancer follow-up, the result is interpreted in relation to the baseline value and other findings.

Your doctor interprets the result together with your symptoms and other findings.

What can affect the result

  • smoking;
  • liver disease and reduced clearance of CEA by the liver;
  • blockage of the bile ducts;
  • inflammatory or infectious digestive diseases;
  • pancreatitis;
  • chronic lung diseases;
  • timing of the sample in relation to surgery or cancer treatment;
  • the tumour's ability to produce CEA;
  • temporary changes that can occur during some treatments;
  • differences between the methods and reagents used by laboratories;
  • high doses of biotin, depending on the method;
  • heterophile antibodies and other interference with immunoassays.

Values obtained by different methods are not always directly comparable.

Related tests

  • Colonoscopy with biopsy – to detect bowel lesions and confirm them histologically;
  • Faecal immunochemical test (FIT) for hidden blood – used to screen eligible people for bowel cancer;
  • Histopathology – needed to confirm the diagnosis and determine the type of tumour;
  • CT, MRI or PET-CT – depending on the type of cancer, the stage and any suspicion of recurrence or metastases;
  • Full blood count, transaminases, alkaline phosphatase, GGT and bilirubin – for a general assessment and to identify conditions that can affect CEA;
  • CA 19-9 – may complement the assessment in some pancreatic, biliary or digestive tumours;
  • CA 125 and other tumour markers – depending on the site and type of the suspected or known tumour;
  • Calcitonin – the main marker used together with CEA to monitor medullary thyroid carcinoma;
  • Calcitonin and CEA doubling time – can give prognostic information in people with medullary thyroid carcinoma;
  • Germline RET gene testing – recommended for everyone with medullary thyroid carcinoma, to identify a possible inherited form, together with genetic counselling;
  • Molecular tumour tests – may be recommended in bowel cancer to characterise the tumour and guide treatment;
  • Assessment by an oncologist, gastroenterologist, surgeon or endocrinologist – depending on the diagnosis and the clinical situation.

How to order tests online?

Add the tests you want to your cart

Choose the tests you need and add them to your cart. Use the site search to find the tests you want more easily.

Pay online or at the laboratory

Payment method:

  • Online – payment uses 3D-Secure, a secure authentication protocol that minimises the risk of fraud.
  • At the laboratory – order your tests online and pay for them when you come to the laboratory.
Have your samples taken at one of our laboratories

After payment, you will receive an email confirming your order, with details of how to prepare for sampling. From then on, you can go to the Sante laboratory you chose when ordering your tests and have your samples taken.

Learn more
Back to top